Reported Earnings • May 15
First quarter 2026 earnings released: NT$0.47 loss per share (vs NT$0.52 loss in 1Q 2025) First quarter 2026 results: NT$0.47 loss per share (improved from NT$0.52 loss in 1Q 2025). Revenue: NT$308.4m (up 70% from 1Q 2025). Net loss: NT$142.2m (loss narrowed 9.5% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Reported Earnings • Mar 14
Full year 2025 earnings released: NT$2.51 loss per share (vs NT$2.28 loss in FY 2024) Full year 2025 results: NT$2.51 loss per share (further deteriorated from NT$2.28 loss in FY 2024). Revenue: NT$1.01b (flat on FY 2024). Net loss: NT$760.6m (loss widened 8.9% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 20% per year. Ankündigung • Mar 10
EirGenix Inc., Annual General Meeting, May 29, 2026 EirGenix Inc., Annual General Meeting, May 29, 2026. Location: 2 floor no,8, sec.2 sheng i rd., jhubei city, hsinchu county Taiwan New Risk • Nov 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change). Reported Earnings • Nov 15
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: NT$0.20 loss per share (improved from NT$0.84 loss in 3Q 2024). Revenue: NT$229.0m (down 7.7% from 3Q 2024). Net loss: NT$60.3m (loss narrowed 77% from 3Q 2024). Revenue missed analyst estimates by 23%. Earnings per share (EPS) exceeded analyst estimates by 67%. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 17
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: NT$1.23 loss per share (further deteriorated from NT$0.72 loss in 2Q 2024). Revenue: NT$230.6m (down 6.4% from 2Q 2024). Net loss: NT$370.8m (loss widened 68% from 2Q 2024). Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) also missed analyst estimates by 137%. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Major Estimate Revision • Jun 21
Consensus revenue estimates fall by 39% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from NT$2.42b to NT$1.49b. Forecast losses increased from -NT$0.68 to -NT$0.90 per share. Life Sciences industry in Taiwan expected to see average net income growth of 19% next year. Consensus price target down from NT$128 to NT$117. Share price rose 5.5% to NT$65.50 over the past week. Price Target Changed • Jun 21
Price target decreased by 8.6% to NT$117 Down from NT$128, the current price target is an average from 2 analysts. New target price is 78% above last closing price of NT$65.50. Stock is down 24% over the past year. The company is forecast to post a net loss per share of NT$0.90 next year compared to a net loss per share of NT$2.28 last year. Reported Earnings • May 15
First quarter 2025 earnings released: NT$0.52 loss per share (vs NT$0.34 loss in 1Q 2024) First quarter 2025 results: NT$0.52 loss per share (further deteriorated from NT$0.34 loss in 1Q 2024). Revenue: NT$181.9m (down 17% from 1Q 2024). Net loss: NT$157.1m (loss widened 51% from 1Q 2024). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Ankündigung • May 06
EirGenix Inc. to Report Q1, 2025 Results on May 13, 2025 EirGenix Inc. announced that they will report Q1, 2025 results at 2:30 PM, Taipei Standard Time on May 13, 2025 Reported Earnings • Mar 19
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: NT$2.28 loss per share (improved from NT$3.00 loss in FY 2023). Revenue: NT$1.01b (down 1.3% from FY 2023). Net loss: NT$698.3m (loss narrowed 24% from FY 2023). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Ankündigung • Mar 05
EirGenix Inc. to Report Fiscal Year 2024 Results on Mar 12, 2025 EirGenix Inc. announced that they will report fiscal year 2024 results on Mar 12, 2025 New Risk • Jan 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NT$454m net loss in 2 years). Share price has been volatile over the past 3 months (6.1% average weekly change). Ankündigung • Jan 24
USFDA Issues Study May Proceed Letter to EirGenix for the Phase III Clinical Trial of Developmental Product Eg1206a (Pertuzumab Biosimilar) EirGenix Inc. announced that it has issued a study may proceed letter to EirGenix for the Phase III clinical trial of EG1206A (pertuzumab biosimilar). Indication: Early breast cancer (EBC) and metastatic breast cancer (MBC). Planned development stages: IND: Completed (2) Phase I: Completed Phase III: The USFDA has issued a study may proceed Letter to EirGenix for The Phase III clinical trial of the developmental product EG1206A (pertizumab biosimilar). BLA/MAA: Not yet started. Current development stage: Application submission/approval/approval/disapproval/each of clinical trials (include interim analysis): The USFDA has issuing a study may proceed letter toEirGenix for the Phase II clinical trial of the developmental productEG1206A (pertuzUMab biosimilar). Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant sense, the risks & the associated measures the Company may occur: After completing the Phase III clinical trial of the Development product EG1206A (expertuzumab biosimilar). The Company will submit a marketing application to regulatory agency (4) Accumulated investment expenditure incurred: The information may affect the licensing deal during the future international negotiation. To protect the rights and interests of the Company and investors, it will not be disclosed publicly. Upcoming development plan: Estimated date of completion: The actual completion time will depend on the regulatory agency review and the progress of trial enrollment. The Company will disclose relevant information in accordance with regulations. Estimated responsibilities: None. Ankündigung • Jan 06
EirGenix, Inc. Officially Submits NDA for the Biosimilar Drug EIRGASUN of 420 Mg Lyophilized Powder for Intraous Administration to the TFDA EirGenix Inc., has officially submitted NDA for the biosimilar drug EIRGASUN of 420 mg lyophilized powder for intravenous administration to the TFDA. New drug name or code: EG12014 (EIRGASUN) (trastuzumab biosimilar). Indication: The treatment of HER2 overexpressing early breast cancer, metastatic breast cancer and metastatic gastric cancer. Planned development stages: This application pertains to the registration of a previously approved biological product with different strength and packaging from different manufacturing sites. The drug product manufacturing facility is Formosa Laboratories Inc. and TFDA is currently reviewing status after the GMP inspection. Current development stage: Application submission/approval/disapproval/each of clinical trials (include interim analysis): Submit New Drug Application (NDA) for EIRGASUN 420 mg lyophilized powder for intravenous administration to the Taiwan Food and Drug Administration (TFDA). After obtaining official approval or the results of statistically significant sense, the future strategy: Once EG12014 420 mg lyophilized powder for intravenous administration is approved in Taiwan, it will have a positive impact on EirGenix's business operation in the future. Accumulated investment expenditure incurred: It was agreed not to disclose this information publicly to protect the company and investors' rights according to the signed confidentiality agreement with Sandoz AG. Upcoming development plan: Estimated date of completion: The review time is based on the process of TFDA. The actual review and approval time are the decision of the TFDA and are subject to the official notification of the TFDA. Ankündigung • Dec 26
EirGenix Inc. Officially Submits the Phase III Clinical Trial Application for the Developmental Product EG1206A (pertuzumab Biosimilar) in US FDA EirGenix has officially submitted the Phase III clinical trial application for the developmental product EG1206A (pertuzumab biosimilar) in US FDA. Early breast cancer (EBC) and metastatic breast cancer (MBC) 4.Planned development stages: (1) IND: Completed (2) Phase I: Completed (3) Phase III: EirGenix has officially submitted Phase III clinical trial application in US FDA. (4) BLA/MAA: Not yet started. 5.Current development stage: (1)Application submission/approval/disapproval/each of clinical trials (include interim analysis): EirGenix has officially submitted Phase III clinical trial application in US FDA. (2)Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant sense, the risks & the associated measures the Company may occur: N/A (3)After obtaining official approval or the results of statistically significant sense, the future strategy: After completing the Phase III clinical trial for the developmental product EG1206A (pertuzumab biosimilar), the company will submit a marketing application to regulatory agency. New Risk • Dec 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NT$480m net loss in 2 years). Share price has been volatile over the past 3 months (6.3% average weekly change). Major Estimate Revision • Dec 12
Consensus revenue estimates fall by 16% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from NT$1.07b to NT$895.0m. Forecast losses increased from -NT$1.94 to -NT$2.61 per share. Life Sciences industry in Taiwan expected to see average net income growth of 50% next year. Consensus price target down from NT$120 to NT$115. Share price fell 20% to NT$73.50 over the past week. Reported Earnings • Nov 15
Third quarter 2024 earnings: EPS exceeds analyst expectations Third quarter 2024 results: NT$0.84 loss per share (further deteriorated from NT$0.37 loss in 3Q 2023). Revenue: NT$248.2m (up 17% from 3Q 2023). Net loss: NT$256.1m (loss widened 129% from 3Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.3%. Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Ankündigung • Nov 05
EirGenix Inc. to Report Q3, 2024 Results on Nov 12, 2024 EirGenix Inc. announced that they will report Q3, 2024 results on Nov 12, 2024 Reported Earnings • Aug 17
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: NT$0.72 loss per share (further deteriorated from NT$0.64 loss in 2Q 2023). Revenue: NT$246.4m (up 78% from 2Q 2023). Net loss: NT$220.6m (loss widened 14% from 2Q 2023). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 2.9%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Ankündigung • Aug 01
EirGenix Inc. to Report Q2, 2024 Results on Aug 08, 2024 EirGenix Inc. announced that they will report Q2, 2024 results on Aug 08, 2024 Major Estimate Revision • May 30
Consensus revenue estimates fall by 28% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from NT$2.29b to NT$1.64b. Forecast loss of -NT$1.00, down from profit of NT$1.09 per share profit previously. Life Sciences industry in Taiwan expected to see average net income growth of 39% next year. Consensus price target down from NT$133 to NT$113. Share price was steady at NT$79.10 over the past week. Breakeven Date Change • May 29
No longer forecast to breakeven The analyst covering EirGenix no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of NT$65.0m in 2024. New forecast suggests the company will make a loss of NT$413.0m in 2025. Reported Earnings • May 18
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2024 results: NT$0.34 loss per share (improved from NT$0.67 loss in 1Q 2023). Revenue: NT$219.7m (up 1.6% from 1Q 2023). Net loss: NT$104.0m (loss narrowed 49% from 1Q 2023). Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) exceeded analyst estimates by 42%. Revenue is forecast to grow 47% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Ankündigung • May 02
EirGenix Inc. to Report Q1, 2024 Results on May 09, 2024 EirGenix Inc. announced that they will report Q1, 2024 results on May 09, 2024 Breakeven Date Change • Apr 23
Forecast breakeven date pushed back to 2025 The analyst covering EirGenix previously expected the company to break even in 2024. New forecast suggests the company will make a profit of NT$413.0m in 2025. Average annual earnings growth of 144% is required to achieve expected profit on schedule. Reported Earnings • Mar 26
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: NT$3.00 loss per share (further deteriorated from NT$0.38 loss in FY 2022). Revenue: NT$1.02b (down 31% from FY 2022). Net loss: NT$915.2m (loss widened NT$799.7m from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 67%. Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Ankündigung • Mar 09
EirGenix Inc., Annual General Meeting, May 30, 2024 EirGenix Inc., Annual General Meeting, May 30, 2024, at 09:30 Taipei Standard Time. Location: International Conference Hall, R&D Center, Hsinchu Biomedical Park 2F, No. 8, Sec. 2, Shengyi Rd., Zhubei City, Hsinchu County Zhubei Taiwan Agenda: To consider Report the business results of 2023; to Audit Committee’s review report; to The 2023 implementation report for the sound business plan; to Amendment to the Regulations Governing Procedure for Board of Directors Meetings; to Discontinue the Private Security Offering Approved by 2023 Shareholders' Meeting; to Remuneration policy for the directors of 2023; to Accept 2023 financial statements and business report; to Ratification of the 2023 deficit offset proposal; and to consider other matters if any. Major Estimate Revision • Feb 06
Consensus revenue estimates fall by 18% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from NT$1.24b to NT$1.02b. Forecast losses increased from -NT$0.89 to -NT$1.80 per share. Life Sciences industry in Taiwan expected to see average net income growth of 28% next year. Consensus price target down from NT$155 to NT$133. Share price was steady at NT$91.80 over the past week. Price Target Changed • Feb 05
Price target decreased by 16% to NT$133 Down from NT$158, the current price target is an average from 2 analysts. New target price is 44% above last closing price of NT$91.80. Stock is down 23% over the past year. The company is forecast to post a net loss per share of NT$1.80 next year compared to a net loss per share of NT$0.38 last year. Ankündigung • Nov 23
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC EirGenix Inc. announced that its trastuzumab biosimilar medicine (EG12014) which their commercial partner Sandoz plans to commercialize (150 mg, for intravenous use) had received a marketing authorization from the European Commission (EC). The marketing authorization in the EU will cover the treatment of human epidermal growth factor receptor 2 positive (HER2-positive) breast cancer and metastatic gastric cancers, which are the same indications approved by the EC for the reference biologic, Herceptin(R). Sandoz AG and EirGenix signed a license agreement in April 2019. Under this agreement, EirGenix Inc. will remain responsible for the development and manufacturing of trastuzumab while Sandoz will hold the rights to commercialize the medicine upon approval in the global market (excluding Taiwan, China, Russia, and some Asian countries). Breast and gastric cancers are among the most frequently occurring in Europe, and combined, are responsible for nearly 200,000 deaths annually. Biosimilars have enormous potential to improve cancer care by substantially increasing access to these critical medicines. The impact of both breast and gastric cancer in Europe is significant. Each year, over 355,000 women are diagnosed with breast cancer, and with 92,000 deaths per year, it is the number one cause of cancer death among women. Gastric cancer is the sixth most common of all cancer types and with 107,000 deaths annually it is the fourth most common cause of cancer-related death in Europe. In up to 20% of breast cancers and up to 30% of gastric cancers diagnosed, a HER2 protein overexpression (or HER2 gene amplification) is detected resulting in an uncontrollable growth and division of cells. HER2 cancers are particularly aggressive cancer types that respond well to targeted treatment. The authorisation of EG12014 in Europe expands access to a vital, high-quality treatment for breast and gastric cancers helping to ease the burden of these diseases on patients and delivering important savings for healthcare systems to ensure sustainability. EirGenix's trastuzumab bios biosimilar drug (EG12014) (150 mg lyophilized powder for injection) also received market approval by TFDA in June. The application of the health insurance pricing was approved by the National Health Insurance Administration under the Ministry of Health and Welfare in mid-September, paving the way for the formal launch of the product in Taiwan. EirGenix develops a series of HER2-positive breast cancer product combinations, including the second- generation HER2-positive targeted antibody drug Perjeta(R) (Pertuzumab), which are continuously advancing into the Phase III clinical trial. With the successful market introduction of the products, further market expansion and strengthening of the product's international competitive advantage will be realized. Reported Earnings • Nov 15
Third quarter 2023 earnings: EPS exceeds analyst expectations Third quarter 2023 results: NT$0.37 loss per share (further deteriorated from NT$0.091 loss in 3Q 2022). Revenue: NT$211.5m (down 42% from 3Q 2022). Net loss: NT$111.7m (loss widened 305% from 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 25%. Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Breakeven Date Change • Nov 15 The 2 analysts covering EirGenix previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of NT$113.0m in 2024.
Ankündigung • Sep 20
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System EirGenix Inc.'s biosimilar, Eirgasun vial 150 mg, has been approved by National Health Insurance Administration, Ministry of Health and Welfare to be enrolled in the reimbursement system, it is officially effective from October 1, 2023. Usage: The treatment of HER2 overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric cancer. The price paid is TWD 11,323 per vial at the current market price. Reported Earnings • Aug 10
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: NT$0.64 loss per share (down from NT$0.021 profit in 2Q 2022). Revenue: NT$138.3m (down 59% from 2Q 2022). Net loss: NT$194.1m (down NT$200.5m from profit in 2Q 2022). Revenue missed analyst estimates by 63%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 66% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Price Target Changed • Jun 09
Price target decreased by 7.5% to NT$172 Down from NT$186, the current price target is an average from 2 analysts. New target price is 57% above last closing price of NT$110. Stock is up 25% over the past year. The company is forecast to post a net loss per share of NT$0.13 next year compared to a net loss per share of NT$0.38 last year. Reported Earnings • Mar 21
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Full year 2022 results: NT$0.38 loss per share (further deteriorated from NT$0.17 loss in FY 2021). Revenue: NT$1.48b (down 13% from FY 2021). Net loss: NT$115.5m (loss widened 171% from FY 2021). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 64% per year, which means it is significantly lagging earnings growth. Price Target Changed • Mar 15
Price target decreased by 9.8% to NT$175 Down from NT$194, the current price target is an average from 2 analysts. New target price is 55% above last closing price of NT$113. Stock is up 23% over the past year. The company is forecast to post a net loss per share of NT$0.18 next year compared to a net loss per share of NT$0.18 last year. Ankündigung • Jan 12
EirGenix Inc. Announces Executive Changes EirGenix Inc. announced that Chun-Fu Lu, Chairman, Foxconn Technology Co. Ltd., has replaced Jih-Luh Tang as Representative of Juristic Person as Director, effective January 10, 2023. Breakeven Date Change • Dec 31
Forecast breakeven date pushed back to 2023 The 2 analysts covering EirGenix previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of NT$710.0m in 2023. Average annual earnings growth of 105% is required to achieve expected profit on schedule. Ankündigung • Dec 29
Eirgenix Inc. Announces Establishment of Corporate Governance Committee EirGenix Inc. announced the establishment of the company's Corporate Governance Committee with Lee-Cheng Liu: President & CEO, EirGenix, Inc; Ming-Thaur Chang: Independent Director, DBS Bank (Taiwan) Ltd.; Fu-Shiow Yin: Independent Director, Foresee Pharmaceuticals Co. Ltd.; Ming-Shen Chen: Professor of Finance at National Taiwan University.; and Po-Chih Chen: Senior Advisors to the President, effective December 28, 2022. Mr. Ming-Shen Chen is the chairman of first term Corporate Governance Committee. Price Target Changed • Nov 29
Price target increased to NT$169 Up from NT$156, the current price target is an average from 2 analysts. New target price is 27% above last closing price of NT$133. Stock is up 20% over the past year. The company is forecast to post earnings per share of NT$0.02 next year compared to a net loss per share of NT$0.18 last year. Reported Earnings • Nov 16
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: NT$0.09 loss per share (down from NT$1.36 profit in 3Q 2021). Revenue: NT$361.6m (down 45% from 3Q 2021). Net loss: NT$27.6m (down 108% from profit in 3Q 2021). Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates by 70%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 68% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Po-Chih Chen was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 13
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: NT$0.09 loss per share (down from NT$1.36 profit in 3Q 2021). Revenue: NT$361.6m (down 45% from 3Q 2021). Net loss: NT$27.6m (down 108% from profit in 3Q 2021). Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates by 70%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 58% per year, which means it is significantly lagging earnings growth. Ankündigung • Sep 10
EirGenix Inc. Appoints Po-Chih Chen as Remuneration Committee EirGenix Inc. announced the appointment of Po-Chih Chen as Remuneration Committee, effective from September 8, 2022. Reported Earnings • Aug 16
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: EPS: NT$0.02 (up from NT$0.65 loss in 2Q 2021). Revenue: NT$336.6m (down 9.6% from 2Q 2021). Net income: NT$6.42m (up NT$154.1m from 2Q 2021). Profit margin: 1.9% (up from net loss in 2Q 2021). The move to profitability was driven by lower expenses. Revenue missed analyst estimates by 31%. Earnings per share (EPS) exceeded analyst estimates. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 16
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: NT$0.05 (up from NT$1.12 loss in 1Q 2021). Revenue: NT$361.5m (up 48% from 1Q 2021). Net income: NT$13.9m (up NT$243.9m from 1Q 2021). Profit margin: 3.8% (up from net loss in 1Q 2021). The move to profitability was primarily driven by higher revenue. Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 92%. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. Price Target Changed • Apr 27
Price target decreased to NT$129 Down from NT$156, the current price target is an average from 2 analysts. New target price is 41% above last closing price of NT$91.00. Stock is down 33% over the past year. The company is forecast to post earnings per share of NT$1.18 next year compared to a net loss per share of NT$0.18 last year. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Director Ming-Thaur Chang was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 03
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: NT$0.18 loss per share (up from NT$5.41 loss in FY 2020). Revenue: NT$1.70b (up 58% from FY 2020). Net loss: NT$42.6m (loss narrowed 96% from FY 2020). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 5.3%. Over the next year, revenue is forecast to grow 32%, compared to a 38% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Mar 30
EirGenix Inc. Announces Replacement of Representative of Juristic Person as Director EirGenix Inc. appointed Kao, Wei-Feng Senior Technical Specialist, National Development Council as Representative of Juristic Person as Director in place of Lin, Jing-Jer, effective April 18, 2022. Price Target Changed • Mar 19
Price target decreased to NT$129 Down from NT$156, the current price target is an average from 2 analysts. New target price is 36% above last closing price of NT$94.30. Stock is up 6.8% over the past year. The company is forecast to post a net loss per share of NT$0.19 next year compared to a net loss per share of NT$5.41 last year. Ankündigung • Feb 07
EirGenix Inc. Officially Submitts for Phase I Pkbiosimilarity Clinical Study of Developmental Product EG1206A (Proposed Pertuzumab Biosimilar) in Europe EirGenix submitted for the Phase I PK biosimilarity clinical study in healthy volunteer's (EGC101, Eudra CT-NR. 2021-006769-40) its clinical trial application of developmental product EG1206A (proposed Pertuzumab biosimilar) to the agency of the German National Competent Authority and the local Ethic Committee on 28th Jan 2022 (CET). Reported Earnings • Nov 15
Third quarter 2021 earnings released: EPS NT$1.36 (vs NT$0.34 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$656.6m (up 67% from 3Q 2020). Net income: NT$332.1m (up NT$401.9m from 3Q 2020). Profit margin: 51% (up from net loss in 3Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 49% per year, which means it is well ahead of earnings. Ankündigung • Sep 24
EirGenix Inc. announced that it expects to receive TWD 2.51625 billion in funding from Foxconn Technology Co., Ltd. EirGenix Inc. announced that it has signed a letter of intent for a private placement of 27,500,000 shares at a price of TWD 91.5 per share for a gross proceeds of TWD 2,516,250,000 on September 22, 2021. The transaction will include participation from new investor Foxconn Technology Co., Ltd. for 9.21% stake in the company. The transaction was approved by the shareholders of the company. Reported Earnings • Aug 15
Second quarter 2021 earnings released: NT$0.65 loss per share (vs NT$1.74 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: NT$372.4m (up 77% from 2Q 2020). Net loss: NT$147.7m (loss narrowed 55% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 57% per year, which means it is well ahead of earnings. Reported Earnings • May 18
First quarter 2021 earnings released: NT$1.11 loss per share (vs NT$2.06 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: NT$244.8m (up 5.6% from 1Q 2020). Net loss: NT$230.1m (loss narrowed 34% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 74% per year, which means it is well ahead of earnings. Major Estimate Revision • Apr 13
Consensus EPS estimates fall to -NT$3.41 The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from NT$1.77b to NT$1.74b. Losses expected to increase from -NT$2.84 to -NT$3.41. Life Sciences industry in Taiwan expected to see average net income growth of 31% next year. Consensus price target of NT$122 unchanged from last update. Share price rose 36% to NT$160 over the past week. Reported Earnings • Mar 27
Full year 2020 earnings released: NT$5.41 loss per share (vs NT$5.39 loss in FY 2019) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: NT$1.07b (up 125% from FY 2019). Net loss: NT$1.04b (loss widened 21% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 51% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 19
New 90-day high: NT$54.20 The company is up 5.0% from its price of NT$51.70 on 20 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 29% over the same period. Is New 90 Day High Low • Jan 22
New 90-day low: NT$39.05 The company is down 32% from its price of NT$57.30 on 23 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 37% over the same period. Is New 90 Day High Low • Jan 04
New 90-day low: NT$44.35 The company is down 30% from its price of NT$63.00 on 07 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 28% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Dec 09
New 90-day low: NT$49.15 The company is down 22% from its price of NT$62.80 on 11 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Analyst Estimate Surprise Post Earnings • Nov 14
Revenue beats expectations, earnings disappoint Revenue exceeded analyst estimates by 41%. Earnings per share (EPS) missed analyst estimates by 69%. Over the next year, revenue is forecast to grow 128%, compared to a 32% growth forecast for the Life Sciences industry in Taiwan. Reported Earnings • Nov 14
Third quarter 2020 earnings released: NT$0.34 loss per share The company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$392.5m (up 338% from 3Q 2019). Net loss: NT$69.8m (loss narrowed 77% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Nov 01
New 90-day low: NT$52.50 The company is down 7.0% from its price of NT$56.40 on 03 August 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 
